Background: In the absence of the existing acute coronary syndrome (ACS) guidelines directing the clinical
better align resources used for this evaluation with diagnostic yield. Despite the need for flexibility in the implementation of clinical practice across EDs with different resources and capabilities, current clinical evidence provides opportunities to reduce variations for this well-researched disease process across EDs. [4] [5] [6] [7] [8] Reducing practice variability for clinical decisions supported with evidence may improve care quality and consistency. 9 Quantifying variable clinical practice is a critical step in understanding current implementation practices and adapting to emerging technologies and health financing reforms. 10 Screening and diagnostic activities that are often predetermined for practitioners within an ED include methods of screening to identify patients for an early electrocardiogram (ECG) to diagnose ST-elevation myocardial infarction (STEMI), the use of serum troponin biomarkers for non-ST-elevation myocardial infarction (NSTEMI) diagnosis, and the integration of noninvasive testing (NIVT) into the identification of obstructive coronary artery disease (CAD) or inducible ischemia. National guidelines for ACS screening and diagnosis exist, [11] [12] [13] but do not inform the implementation of ACS diagnostic care upon patient contact with the healthcare system. Variation in clinical practices, for similar individuals suspected of having a similar disease process, may expose patients to a different evaluation and medical course dependent on the ED they enter for care.
Our objective was to characterize system-level ACS screening and diagnostic practices across U.S. EDs. In the absence of clinical guidelines directing clinical practice implementation in the ED, we suspected there is variable use of ECGs to screen for STEMI, troponin biomarkers and pretroponin risk stratification to identify NSTEMI, and NIVT for the identification of CAD or inducible ischemia. The study is not intended to differentiate whether variability reflects under-or overuse of resources. Rather it is a general examination of the presence of clinical practice differences to identify candidate opportunities for more consistent and evidence-based practice.
METHODS

Study Hypotheses
We specifically explore three domains of screening and diagnostic practice: 1) variability in the criteria used by EDs to identify patients who require an early ECG to diagnose STEMI, 2) nonuniform troponin biomarkers and formalized pretest risk-stratification use for the diagnosis of NSTEMI, and 3) variation in the use of NIVT to detect inducible ischemia or identify obstructive CAD.
Study Design
This is a cross-sectional clinical practice epidemiology study design to characterize ED ACS clinical practice patterns, with the ED as the unit of analysis. Data were collected via survey as reported by each member ED's site primary investigator (site-PIs). Most frequently site-PIs are medical or clinical operations directors. However, the group includes directors of research, nurse administrators, and research faculty with clinical operations interests. To measure STEMI screening practice across institutions we identified the criteria used to trigger an early ECG to diagnose STEMI into five categories based on prior studies presenting ACS symptoms. These categories were chest pain, atypical symptoms (shortness of breath, abdominal pain), associated symptoms (jaw pain, shoulder pain, back pain, dizziness, diaphoresis), use of an age threshold, and other. [14] [15] [16] [17] [18] Our investigation of NSTEMI and noninfarction ischemia diagnostic practice (NSTE-ACS) included the timing of troponin biomarkers sampling. Our focus for noninfarction ischemia included identifying the modality and location of non-NIVT. Institutional review board approval was obtained prior to the initiation of this study.
Study Population
With the ED as the unit of analysis, our study population included 62 facility members of the Emergency Department Operations Study Group (EDOSG) reflecting a total of 3,323,071 ED visits in 2014. The EDOSG is a research consortium promoting evidencebased clinical practice management with attention to patient focused metrics and outcomes. The group represents the diversity of US EDs in terms of U.S. geographic regions, infrastructure, patient acuity, annual patient volume, academic intensity, and clinical staffing differences (see Table 1 ).
Data Collection
Each site-PI completed a 15-question tool identifying specific ACS diagnostic practices for each ED. The questions were imbedded within the EDOSG's 2015 annual data collection process reflecting 2014 practice and performance collected via the Baseline Data Collection Tool (BDCT; see Data Supplement S1, available as supporting information in the online version of record of this paper, which is available at http:// onlinelibrary.wiley.com/doi/10.1111/acem.13184/full). The BDCT was developed and refined over the course of 7 years with a continued review of the literature; use of clinical experience; and virtual focus groups with ED medical directors, clinical operations leaders, and department chairs to determine the feasibility of data collection prior to study initiation. 19 In addition to the questions regarding ACS practice, we obtained facility demographics and annual aggregate clinical operations measures from the EDOSG for all ED participants. These added details include data such as laboratory test turn-around-times, staffing, and ED admission rates (Data Supplement S1).
A data collection instruction set (see Data Supplement S2, available as supporting information in the online version of record of this paper, which is available at http://onlinelibrary.wiley.com/doi/10.1111/acem. 13184/full). was provided including definitions for each study variable, units of measurement for reporting, and direction on where the data were likely to be available within a health system. The guidance provided in the instruction set was based on the EDOSG's experience with prior ED data collection efforts. 19 All EDs employed an electronic medical record system that reduces the likelihood of measurement errors in data collection compared to data extraction from paper documentation. Site-PIs coordinated the extraction of the study data from their record system and data requests from hospital administrators who preaggregate data for internal performance monitoring or external reporting (i.e., case mix index, annual ED volume, admission rates). The study data were submitted via a Microsoft Word or hard-copy data collection tool (Data Supplement S1) and then scanned and e-mailed, faxed, or postal mailed to the EDOSG via the Emergency Medicine Health Services Research Data Coordinating Center (EM HSR-DCC) at Vanderbilt University.
Data Validity and Reliability
Data provided by each site-PI were reviewed for completeness and validity by the study coordinator prior to entry into the study REDCap database (https://pro jectredcap.org/). REDCap is a secure, Vanderbilt-developed, Web-based application designed exclusively to support data capture in widespread use worldwide. Any values falling outside of the range of prior EDOSG data were verified with the site-PI for accuracy. The study coordinator followed up with the site-PI to identify whether missing data were unobtainable or not reported. If obtainable, the data were requested and included if available within 6 months. Once data collection was closed, the full data set was reviewed by the study lead (MY) and HSR-DCC biostatisticians (DL and XL) for accuracy and consistency.
Data Analysis
Data were reported as aggregated counts, means, and proportions for measures of resource utilization, process, and performance. We used descriptive statistics to report summaries as percentages and median with 
RESULTS
We achieved 100% data return, of which 77% of the EDs study data were complete. For STEMI screening we found that 85% of EDs utilize a formal triage protocol to identify patients for an early ECG. Of these, 17% use chest pain as the sole screening criteria (see Table 2 ). For NSTE-ACS only 34% of EDs routinely risk stratify before troponin testing. Similarly, 35% use a common definition to identify patients with a low risk for ischemia. Specific to the use of troponin biomarkers for diagnosis, we found the mean (AESD) and median (IQR) delta troponin intervals were 240 (180-360) and 256 (AE108) minutes, respectively. A minority of EDs (13%) use intervals less than or equal to 2 hours, while the majority (58%) use intervals greater than or equal to 4 hours. The time from physician order to first result, or turnaround time, had a median (IQR) of 53 (33-68) minutes and mean (AESD) of 53 (AE25) minutes (see Table 3 ). We examined whether there was a correlation between the use of routine pretroponin risk stratification and reported delta troponin intervals and did not find a significant association (Spearman correlation coefficient = -0.044 [-0.252, 0.314]).
We found the median percentage of patients who have NIVT performed during their ED visit is 5% with limited variation (IQR = 2-10%). However, the mean of 22% with a SD AE 34% suggests strong rightward outliers. The mean and median percentages of patients referred for further ischemic testing in hospital (in patient or admission) were 70% (30%-95%) and 61% (AE34%), respectively. We found a weak negative correlation (Spearman correlation coefficient = -0.202 [-0.456, 0.073]) between the use of routine pretroponin risk stratification and frequency of inhospital referral for testing. Coronary CT angiography was an available resource for ACS evaluation in 66% of EDs. Exercise treadmill testing was the most frequently reported first-line NIVT (42%). However, the majority of EDs (58%) used alternative modalities. Only 41% had an established clinical policy guiding the uses of NIVT (see Table 4 ).
DISCUSSION
Our review of ACS screening and diagnostic practices within emergency medicine identified clinical practice variation relating to STEMI, NSTEMI, and obstructive CAD or inducible ischemia. We acknowledge physician-to-physician practice variation. 20 However, this investigation sought to capture the general practice of physician groups working within individual EDs, with the ED as the unit of study. This system perspective recognizes the availability of diagnostic tools is often contingent on preestablished institutional decisions and ED performance; both are often outside of a provider's immediate control. 21 
STEMI: Screening for an Early ECG
We found that 85% of EDs have structured patient screening for STEMI. Of this group, the majority use a combination of typical, atypical, and associated symptoms. However, 17% use "chest pain" as the only criterion to identify patients for an early ECG. The 2013 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines for the identification of STEMI recommend acquiring an ECG within 10 minutes of arrival in an ED for "patients with chest pain or other symptoms suggestive of ACS." 12, 13 There is no discussion on how to screen the broader ED population or which "other symptoms" to consider. Over 20 years of research on presenting symptoms for STEMI identified that 20% to 30% of patients never report "chest pain." 20, 21 Investigations into the characteristics of these "atypical" presentations have noted higher proportions of women, diabetics, elderly, and minorities. [16] [17] [18] A robust 2012 study of ED patients recommended a screening protocol consisting of a combination of typical, atypical, and associated myocardial ischemia symptoms along with age thresholds. 22 The limited evidence-based clinical practice penetration identified in our study raises concerns that patient are exposed to diagnostic and treatment delays due to inadequate screening in specific EDs.
Variable screening criteria may introduce systematic bias in the timely identification and treatment of select patient groups for STEMI that warrants further investigation to ensure equitable care. In contrast, screening variability may be appropriately related to differences in the triage process and physician wait times in different EDs. For example, those with longer door-to-doctor times may require more robust triage screening for ACS to mitigate the risk of diagnostic delay. Conversely, EDs with shorter door-to-doctor times may aim to restrict prolonged triage evaluations by using fewer screening criteria. There is likely to be a threshold were low diagnostic yield leads to a gross imbalance in the resources diverted away from other acute care to produce and interpret false-positive screens. In prior work examining screening criteria for an early ECG to diagnose STEMI across EDs, there was no association between the number of criteria included and the proportion of STEMI patients with delayed time to ECG. 23 Whether STEMI screening criteria effects timely diagnosis or treatment, and whether triage process and door-to-doctor time mitigate the relationship, warrants further study to inform our understanding of best STEMI screening practice.
NSTEMI: Use of Troponin Biomarkers
The diagnosis of NSTEMI includes identifying a serum troponin elevation three times the upper limit for a normal and healthy population. 24 Over the past 20 years, the time interval from onset of ischemia to troponin elevation diagnostic for necrosis has decreased due to improvements in the troponin biomarker technology. [25] [26] [27] The minimal interval used to detect a rise has reduced from 18 hours in the 1990s to 3 hours with recent studies. [28] [29] [30] [31] This has moved the diagnostic evaluation of NSTEMI from the inpatient setting to the ED. This can decreased the overall in-hospital time, but can increase the amount of diagnostic time the typical "rule-out ACS" patient requires from ED. In our study population, the mean and median delta troponin interval was approximately 4 hours and 58% of EDs used an interval that was equal to or greater than 4 hours. Adjusting the delta troponin interval to 3 hours for appropriate assays is a potential opportunity to expedite NSTEMI diagnosis. Intervals longer than 3 hours are not likely to add value from a health system and resource utilization perspective. In EDOSG = ED Operations Study Group; NSTEMI = non-ST-elevation myocardial infarction. *Delta troponin interval is the time awaited for the second or final troponin to rule out myocardial infarction after a specified time zero (often ED arrival or the onset of symptoms). addition, many authors have proposed criteria for the use of high-sensitivity troponin and clinical criteria for reducing the need for a second troponin.
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The central tendency and practice variability-median (IQR) 240 (180-360) minutes and mean (AESD) 256 (AE108) minutes-are consistent with the ACC/ AHA guidelines for the diagnosis of NSTE-ACS recommending a delta troponin interval of 3 to 6 hours. 13 However, this range approaches the length of an entire ED visit. With regard to clinical practice implementation, it is not clear when to use 3 hours versus 6 hours, nor whether this decision should be based on the assay or the patient pretest risk for ACS.
NST-Elevation ACS: Pretest Risk Stratification for Admit Versus Discharge
There is existing literature on the use of emergency care risk stratification tools to inform decisions on a patient's disposition from the ED. The TIMI and GRACE scores were earlier forms of ACS risk stratification which are in wide use throughout medicine. 36, 37 However, they poorly discriminate among those with low-risk ACS, who are the majority of patients undergoing this evaluation. 38 The HEART score shows promise in standardizing diagnostic decision making. It has been validated and used in a growing number of EDs nationally with specific criteria identifying patients at "low risk" for a major adverse cardiac event. The TIMI, GRACE, and HEART scores, however, all rely on the result of a troponin for stratification. Regardless of this slight limitation, these criteria create common risk stratification language to facilitate care transitions and discussions in the setting of variable provider practice, while permitting the identification of patients with such a low event incidence that further in-hospital care is not warranted. 39, 40 Pretroponin risk stratification can permit medical or case management teams time to coordinate outpatient referral in tandem with other elements of the diagnostic evaluation. With only 34% of EDs routinely performing formalized pretest risk stratification, there may be is a missed opportunity to identify patients for whom admission is not likely early in the ED visit. We did not find a significant correlation between EDs that routinely perform pretroponin risk stratification and the frequency of in-hospital admission (observation and inpatient status) for further testing. Give that the confidence intervals included zero this is not a significant finding within this data sample, but can be explored in a larger data set.
Noninfarction Ischemia: NIVT Destination Finally, noninfarction ischemia is determined at the end of an evaluation for ACS as a diagnosis of exclusion. Associated testing includes exercise treadmill testing, stress echocardiography, nuclear stress imaging, coronary computer tomography angiography, and cardiac magnetic resonance imaging. The ACC/AHA guidelines on the diagnosis and management of NSTE-ACS state that it is reasonable to refer a patent for NIVT to identify inducible ischemia from obstructive CAD via outpatient referral within 72 hours. 13 Current methods for providing this continued testing include the use of prolonged ED visits, in-hospital admission, observation medicine, and discharge with facilitated follow-up. [41] [42] [43] [44] [45] We found that the mean proportion of patients admitted for NIVT was 70%. Since prior work has demonstrated that less than 3.5% of all patients evaluated will have ACS as their final diagnosis, 1 there is a potential opportunity to reduce the use of in-hospital resources and create pathways for facilitated outpatient follow-up. Early risk stratification can permit an increased shift of NIVT from in-hospital or ED to outpatient destinations in those with lower ACS risk or patients with high risk tolerance. 46 
LIMITATIONS
This study is an exploration of ED-level clinical practice per aggregated patient data and reported policies or practice guidelines. As a result it does not include an evaluation of physician practice or individual patient data. The reliability of our study data is dependent on the accurate reporting of each ED's data by the site-PI. Each site-PI, however, was in a position to obtain accurate study data and committed to report precise data. Table 1 demonstrates the ED diversity per available characteristics; however, our results are unadjusted for ED facility and patient population characteristics. Future work should include an adjusted analysis per covariates capturing variability in the patient population and ED facility types.
CONCLUSION
Within emergency medicine the evaluation of acute coronary syndrome is an often overlapping sequence of testing for ST-elevation myocardial infarction followed by non-ST-elevation myocardial infarction and noninfarction ischemia. Our results suggest variable acute coronary syndrome screening and diagnostic clinical practice across EDs in ST-elevation myocardial infarction screening criteria upon arrival, troponin and risk stratification use for non-ST-elevation myocardial infarction, and referral for provocative testing. Exploring this variability further may present opportunities to better synthesize the evidence to balance the intensity of care provided to ED patients with symptoms suggestive of acute coronary syndrome.
